Braidwell LP Lowers Holdings in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Braidwell LP significantly reduced its stake in Dianthus Therapeutics by 68.9%, selling 831,234 shares and now holding 375,355 shares worth approximately $6.81 million.
• Dianthus Therapeutics' share price has dropped by 5.0%, with current trading at $23.57, amid a volatile market and disappointing quarterly earnings results.
• Several institutional investors increased their holdings in Dianthus Therapeutics during the previous quarter, pointing to continued interest from large financial entities in the biotechnology sector.

Braidwell LP cut its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 68.9% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 375,355 shares of the company's stock after selling 831,234 shares during the period. Braidwell LP owned about 1.17% of Dianthus Therapeutics worth $6,809,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of DNTH. Vestal Point Capital LP grew its holdings in shares of Dianthus Therapeutics by 172.2% during the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock worth $23,435,000 after buying an additional 680,000 shares in the last quarter. Octagon Capital Advisors LP grew its holdings in shares of Dianthus Therapeutics by 20.8% in the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after purchasing an additional 363,500 shares during the period. Candriam S.C.A. purchased a new stake in shares of Dianthus Therapeutics in the first quarter valued at about $4,510,000. Janus Henderson Group PLC grew its holdings in shares of Dianthus Therapeutics by 14.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock valued at $23,607,000 after purchasing an additional 136,314 shares during the period. Finally, Moody Aldrich Partners LLC purchased a new stake in shares of Dianthus Therapeutics in the first quarter valued at about $1,349,000. Hedge funds and other institutional investors own 47.53% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Robert W. Baird dropped their price objective on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Wedbush upped their price objective on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the company an "outperform" rating in a report on Thursday, August 21st. Finally, William Blair assumed coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an "outperform" rating for the company. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $54.00.

Dianthus Therapeutics Stock Up 7.5%

DNTH stock traded up $1.84 during mid-day trading on Friday, hitting $26.50. 679,673 shares of the company were exchanged, compared to its average volume of 340,531. The firm has a market capitalization of $853.04 million, a P/E ratio of -8.15 and a beta of 1.46. Dianthus Therapeutics, Inc. has a 12-month low of $13.36 and a 12-month high of $32.27. The business has a fifty day simple moving average of $21.27 and a 200-day simple moving average of $20.08.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. Research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.